博創科技(300548.SZ):2022年度擬向銀行申請合計不超7.5億元綜合授信額度
格隆匯4月7日丨博創科技(300548.SZ)公佈,根據公司2022年度經營發展的需要,公司及全資子公司2022年度擬向銀行申請合計不超過7.5億元人民幣的綜合授信額度,公司及所有全資子公司在此額度內根據實際需求進行銀行借貸時共享使用。授信方式包括但不限於銀行貸款、銀行承兑匯票、信用證和保函等綜合授信業務。同時,公司擬為全資子公司成都蓉博通信技術有限公司(“成都蓉博”)的綜合授信提供不超過2億元人民幣的擔保額度。
上述額度有效期自本次董事會審議通過之日起至2023年4月30日止。上述授信額度最終以各家銀行實際審批為準,具體授信及擔保金額將視公司及子公司的實際需求確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.